To title: further development of ipsc-based vaccine for colon cancer prevention
Active Awarded Last action
- Contract number
- 75N91023F00001
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,293,012
Award facts
- Contract value 100% obligated
- $1,293,012.00 Current and potential, with all options
- Completion date 95% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,293,012 |
About this award
The National Cancer Institute issued a $1,293,012 delivery order to The University of Texas MD Anderson Cancer Center on July 26, 2023, for further development of an induced pluripotent stem cell (iPSC)-based vaccine for colon cancer prevention, with completion scheduled for December 25, 2026.
This delivery order is issued under the PREVENT Preclinical Drug Development Program (PREVENT), a $149,995,000 National Cancer Institute IDIQ supporting preclinical efficacy testing and biomarker evaluation of potential cancer preventive agents through January 24, 2029. Place of performance is Houston, TX.
The order is priced on a firm fixed-price basis with no set-aside applied. In fiscal year 2024, MD Anderson invoiced $430,000 against this order and self-performed all reported labor without subcontractor engagement.
Quick answers
Who was awarded contract 75N91023F00001?
75N91023F00001 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on July 26, 2023.
How much is contract 75N91023F00001 worth?
The government has obligated $1,293,012 on 75N91023F00001.
Is contract 75N91023F00001 an order under another contract?
Yes. 75N91023F00001 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91023F00001 competed?
The extent of competition for 75N91023F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award